Cargando…

In vivo generation of CAR T cells in the presence of human myeloid cells

Pre-clinical humanized mouse models are a powerful tool to evaluate immunotherapies. NSG-SGM3 mice reconstituted with human stem cells (huSGM3) develop pronounced human myeloid cells due to transgenic expression of stem cell factor, granulocyte-macrophage colony-stimulating factor, and interleukin-3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ho, Naphang, Agarwal, Shiwani, Milani, Michela, Cantore, Alessio, Buchholz, Christian J., Thalheimer, Frederic B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249670/ https://www.ncbi.nlm.nih.gov/pubmed/35795778 http://dx.doi.org/10.1016/j.omtm.2022.06.004

Ejemplares similares

In vivo generated human CAR T cells eradicate tumor cells
por: Agarwal, Shiwani, et al.
Publicado: (2019)

Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms
por: Michels, Alexander, et al.
Publicado: (2022)

Dasatinib is a potent enhancer for CAR T cell generation by CD3-targeted lentiviral vectors
por: Braun, Angela H., et al.
Publicado: (2022)

Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4
por: Jamali, Arezoo, et al.
Publicado: (2020)

Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics
por: Charitidis, Filippos T., et al.
Publicado: (2021)

Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics
por: Charitidis, Filippos T., et al.
Publicado: (2022)

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome
por: Pfeiffer, Anett, et al.
Publicado: (2018)

CD62L as target receptor for specific gene delivery into less differentiated human T lymphocytes
por: Kapitza, Laura, et al.
Publicado: (2023)

Biomaterials promote in vivo generation and immunotherapy of CAR-T cells
por: Qin, Ya-Ting, et al.
Publicado: (2023)

CAR models: next-generation CAR modifications for enhanced T-cell function
por: Abate-Daga, Daniel, et al.
Publicado: (2016)

Repolarization of Tumor-Infiltrating Myeloid Cells for Augmentation of CAR T Cell Therapies
por: Luo, Weichuan, et al.
Publicado: (2022)

CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo
por: Golubovskaya, Vita, et al.
Publicado: (2023)

Transdifferentiation of bovine epithelial cells towards adipocytes in the presence of myoepithelium
por: Sugathan, Subi, et al.
Publicado: (2020)

Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia
por: Sánchez Martínez, Diego, et al.
Publicado: (2022)

An Intrinsic Propensity of Murine Peritoneal B1b Cells to Switch to IgA in Presence of TGF-β and Retinoic Acid
por: Roy, Bishnudeo, et al.
Publicado: (2013)

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
por: Ye, Lin, et al.
Publicado: (2019)

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
por: Xin, Tianqing, et al.
Publicado: (2022)

Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo
por: Ho, Jin-Yuan, et al.
Publicado: (2021)

WFH State‐of‐the‐art paper 2020: In vivo lentiviral vector gene therapy for haemophilia
por: Cantore, Alessio, et al.
Publicado: (2020)

In vivo imaging of nanoparticle-labeled CAR T cells
por: Kiru, Louise, et al.
Publicado: (2022)

Rejuvenating Effector/Exhausted CAR T Cells to Stem Cell Memory–Like CAR T Cells By Resting Them in the Presence of CXCL12 and the NOTCH Ligand
por: Ando, Makoto, et al.
Publicado: (2021)

CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions
por: Mardiana, Sherly, et al.
Publicado: (2020)

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2022)

CAR-T Cells Immunotherapies for the Treatment of Acute Myeloid Leukemia—Recent Advances
por: Zarychta, Julia, et al.
Publicado: (2023)

Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?
por: Vainstein, Vladimir, et al.
Publicado: (2023)

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
por: Morgan, Michael A., et al.
Publicado: (2020)

Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs
por: Moghanloo, Ehsan, et al.
Publicado: (2021)

Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy
por: Urak, Ryan, et al.
Publicado: (2017)

Ex Vivo Generation of CAR Macrophages from Hematopoietic Stem and Progenitor Cells for Use in Cancer Therapy
por: Paasch, Daniela, et al.
Publicado: (2022)

Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity
por: Torres Chavez, Alejandro, et al.
Publicado: (2019)

P430: COMBINATORIAL ADAPTOR-MEDIATED TARGETING OF ACUTE MYELOID LEUKEMIA WITH CAR T-CELLS
por: Volta, Laura, et al.
Publicado: (2023)

Genome editing for scalable production of alloantigen‐free lentiviral vectors for in vivo gene therapy
por: Milani, Michela, et al.
Publicado: (2017)

Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts
por: Hartmann, Jessica, et al.
Publicado: (2017)

S263: CYTOPENIAS, AGE AND CAR-HEMATOTOX SCORE PREDICT THE DEVELOPMENT OF POST CAR T-CELL THERAPY-RELATED MYELOID NEOPLASMS
por: Gurney, Mark, et al.
Publicado: (2023)

Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia
por: Gottschlich, Adrian, et al.
Publicado: (2023)

Interactions of Human Myeloid Cells with Natural Killer Cell Subsets In Vitro and In Vivo
por: Chijioke, Obinna, et al.
Publicado: (2011)

Generating CAR T cells from tumor-infiltrating lymphocytes
por: Mills, Jane K., et al.
Publicado: (2021)

Physiological lentiviral vectors for the generation of improved CAR-T cells
por: Tristán-Manzano, María, et al.
Publicado: (2022)

Physiological lentiviral vectors for the generation of improved CAR-T cells
por: Tristán-Manzano, María, et al.
Publicado: (2022)

Transitory presence of myeloid-derived suppressor cells in neonates is critical for control of inflammation
por: He, Yu-Mei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_e7jab7q3ndjricr3hno3lk4usn